NASDAQ:NBIX Neurocrine Biosciences (NBIX) Stock Price, News & Analysis → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free NBIX Stock Alerts $140.08 +1.06 (+0.76%) (As of 09:58 AM ET) Add Compare Share Share Today's Range$138.95▼$140.2550-Day Range$130.40▼$143.7452-Week Range$89.04▼$148.37Volume15,678 shsAverage Volume836,156 shsMarket Capitalization$14.10 billionP/E Ratio38.59Dividend YieldN/APrice Target$147.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Neurocrine Biosciences alerts: Email Address Neurocrine Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.74 Rating ScoreUpside/Downside6.4% Upside$147.88 Price TargetShort InterestHealthy2.01% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.42Based on 46 Articles This WeekInsider TradingSelling Shares$23.78 M Sold Last QuarterProj. Earnings Growth33.68%From $4.78 to $6.39 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.60 out of 5 starsMedical Sector70th out of 905 stocksBiological Products, Except Diagnostic Industry6th out of 154 stocks 2.4 Analyst's Opinion Consensus RatingNeurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.74, and is based on 17 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Neurocrine Biosciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.01% of the outstanding shares of Neurocrine Biosciences have been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently decreased by 16.87%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Previous Next 2.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNeurocrine Biosciences has received a 24.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Valbenazine", "Elagolix", and "Opicapone" products. See details.Environmental SustainabilityThe Environmental Impact score for Neurocrine Biosciences is -2.61. Previous Next 2.5 News and Social Media Coverage News SentimentNeurocrine Biosciences has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 46 news articles for Neurocrine Biosciences this week, compared to 9 articles on an average week.Search InterestOnly 5 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows13 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 44% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,782,885.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurocrine Biosciences' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 33.68% in the coming year, from $4.78 to $6.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 38.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.15.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 38.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 190.21.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 6.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neurocrine Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeGold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Neurocrine Biosciences Stock (NASDAQ:NBIX)Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Read More NBIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBIX Stock News HeadlinesMay 9, 2024 | insidertrades.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 273 Shares of StockApril 18, 2024 | insidertrades.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 19,818 Shares of StockMay 9, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.April 16, 2024 | insidertrades.comThe 5 Stocks Most Sold By Insiders This Year (NBIX)May 9, 2024 | prnewswire.comNeurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024May 9, 2024 | prnewswire.comNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy AdultsMay 9, 2024 | globenewswire.comNxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy AdultsMay 8, 2024 | prnewswire.comNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy AdultsMay 9, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 7, 2024 | prnewswire.comNeurocrine Biosciences to Present at the BofA Securities 2024 Health Care ConferenceMay 7, 2024 | prnewswire.comNeurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024May 7, 2024 | americanbankingnews.comCitigroup Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $150.00May 6, 2024 | prnewswire.comNeurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and MonitoringMay 6, 2024 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) PT Raised to $160.00May 6, 2024 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Increased to $170.00 by Analysts at GuggenheimMay 6, 2024 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $169.00May 6, 2024 | americanbankingnews.comBrokers Issue Forecasts for Neurocrine Biosciences, Inc.'s FY2025 Earnings (NASDAQ:NBIX)May 6, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Cut by William BlairMay 6, 2024 | americanbankingnews.comHC Wainwright Weighs in on Neurocrine Biosciences, Inc.'s Q2 2024 Earnings (NASDAQ:NBIX)May 6, 2024 | americanbankingnews.comWedbush Research Analysts Decrease Earnings Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX)May 4, 2024 | americanbankingnews.comNeurocrine Biosciences' (NBIX) Hold Rating Reiterated at Needham & Company LLCMay 3, 2024 | markets.businessinsider.comMaintaining Hold on Neurocrine Biosciences Amidst Pipeline Potential and Market Valuation ConcernsMay 3, 2024 | prnewswire.comNeurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024May 2, 2024 | msn.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comNeurocrine Biosciences First Quarter 2024 Earnings: EPS Misses ExpectationsMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Neurocrine Biosciences on Strong Performance and Promising PipelineMay 2, 2024 | finance.yahoo.comNeurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...See More Headlines Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/07/2024Today5/08/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:NBIX CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees1,400Year FoundedN/APrice Target and Rating Average Stock Price Target$147.88 High Stock Price Target$216.00 Low Stock Price Target$100.00 Potential Upside/Downside+6.4%Consensus RatingModerate Buy Rating Score (0-4)2.74 Research Coverage23 Analysts Profitability EPS (Most Recent Fiscal Year)$3.63 Trailing P/E Ratio38.30 Forward P/E Ratio29.08 P/E GrowthN/ANet Income$249.70 million Net Margins18.65% Pretax Margin23.71% Return on Equity17.45% Return on Assets12.14% Debt Debt-to-Equity RatioN/A Current Ratio2.52 Quick Ratio2.47 Sales & Book Value Annual Sales$1.98 billion Price / Sales7.06 Cash Flow$2.55 per share Price / Cash Flow54.56 Book Value$22.72 per share Price / Book6.12Miscellaneous Outstanding Shares100,637,000Free Float96,310,000Market Cap$13.99 billion OptionableOptionable Beta0.28 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Kevin C. Gorman Ph.D. (Age 66)CEO & Director Comp: $2.05MMr. Matthew C. Abernethy (Age 44)Chief Financial Officer Comp: $1.06MDr. Jude Onyia Ph.D. (Age 60)Chief Scientific Officer Comp: $1.22MMr. Kyle W. Gano Ph.D. (Age 51)Chief Business Development & Strategy Officer Comp: $990.12kDr. Eiry Wyn Roberts M.D. (Age 60)Chief Medical Officer Comp: $1.12MJane SorensenHead of Investor RelationsMr. Darin M. Lippoldt Esq. (Age 58)Chief Legal Officer & Corporate Secretary Comp: $921.01kMs. Julie S. Cooke (Age 58)Chief Human Resources Officer Mr. Eric S. Benevich (Age 59)Chief Commercial Officer Comp: $805kMr. David Warren Boyer (Age 44)Chief Corporate Affairs Officer More ExecutivesKey CompetitorsAcceleron PharmaNASDAQ:XLRNRepligenNASDAQ:RGENExelixisNASDAQ:EXELMomenta PharmaceuticalsNASDAQ:MNTAHalozyme TherapeuticsNASDAQ:HALOView All CompetitorsInsiders & InstitutionsState Board of Administration of Florida Retirement SystemBought 2,153 shares on 5/9/2024Ownership: 0.109%Mitsubishi UFJ Asset Management Co. Ltd.Bought 14,015 shares on 5/9/2024Ownership: 0.055%Fortis Capital Advisors LLCBought 4,236 shares on 5/9/2024Ownership: 0.004%ProShare Advisors LLCBought 383 shares on 5/8/2024Ownership: 0.012%Donoghue Forlines LLCBought 303 shares on 5/8/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions NBIX Stock Analysis - Frequently Asked Questions Should I buy or sell Neurocrine Biosciences stock right now? 23 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 6 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NBIX shares. View NBIX analyst ratings or view top-rated stocks. What is Neurocrine Biosciences' stock price target for 2024? 23 analysts have issued twelve-month price targets for Neurocrine Biosciences' stock. Their NBIX share price targets range from $100.00 to $216.00. On average, they expect the company's stock price to reach $147.88 in the next year. This suggests a possible upside of 6.4% from the stock's current price. View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts. How have NBIX shares performed in 2024? Neurocrine Biosciences' stock was trading at $131.76 on January 1st, 2024. Since then, NBIX shares have increased by 5.5% and is now trading at $139.02. View the best growth stocks for 2024 here. Are investors shorting Neurocrine Biosciences? Neurocrine Biosciences saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 2,020,000 shares, a drop of 16.9% from the March 31st total of 2,430,000 shares. Based on an average daily volume of 875,200 shares, the days-to-cover ratio is presently 2.3 days. View Neurocrine Biosciences' Short Interest. When is Neurocrine Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our NBIX earnings forecast. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its earnings results on Wednesday, February, 7th. The company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.31. The firm had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 17.45% and a net margin of 18.65%. Neurocrine Biosciences's quarterly revenue was up 25.0% compared to the same quarter last year. During the same period last year, the firm earned $0.88 EPS. What ETFs hold Neurocrine Biosciences' stock? ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), VanEck Biotech ETF (BBH), Goldman Sachs Future Health Care Equity ETF (GDOC), Virtus LifeSci Biotech Products ETF (BBP) and Invesco Bloomberg Pricing Power ETF (DEF). What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO? 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM). Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.93%), Allspring Global Investments Holdings LLC (0.51%), Allspring Global Investments Holdings LLC (0.51%), BNP Paribas Financial Markets (0.43%), Principal Financial Group Inc. (0.42%) and Russell Investments Group Ltd. (0.35%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, George J Morrow, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Leslie V Norwalk, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NBIX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.